ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment"

  • Abstract Number: 1394 • 2017 ACR/ARHP Annual Meeting

    Comparison of Improvements in Disease Activity between Classes of Biologic Disease Modifying Anti-Rheumatic Drugs in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort

    Richard Gliklich1, Zhaohui Su2, Gregory Donadio1, Tom Brecht2, Costas Boussios2, Francis O’Donovan3, Charles Kekeh3, Anna Lafontant2, Kathryn Starzyk2 and Vandana Menon2, 1OM1, Inc, Cambridge, MA, 2Research, OM1, Inc, Cambridge, MA, 3Data Science, OM1, Inc, Cambridge, MA

    Background/Purpose: RA is estimated to affect approximately 1.3 million adults in the US and accounts for a significant proportion of US health care spend with…
  • Abstract Number: 1432 • 2017 ACR/ARHP Annual Meeting

    The Prognostic Value of IgA Subtypes of Rheumatoid Factor and Anti-Citrullinated Protein Antibodies (ACPA)  for Prediction of Therapeutic Responses to TNF Inhibitory Therapy in Patients with Rheumatoid Arthritis

    Daniela Sieghart1, Farideh Alasti2, Paul Studenic1 and Günter Steiner2, 1Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, 2Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Rheumatoid factor (RF) and Anti-Citrullinated Protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the…
  • Abstract Number: 1444 • 2017 ACR/ARHP Annual Meeting

    Targeted Therapeutic Delivery to Cartilage with Knottin Proteins

    Emily Girard, Michelle Cook Sangar, Gene Hopping, Fiona Pakiam and James Olson, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

    Background/Purpose: Arthritic diseases affect more than 50 million Americans and, although there are many etiologies, the common manifestation of the disease is pain and limited…
  • Abstract Number: 609 • 2016 ACR/ARHP Annual Meeting

    Economic Impact of Adalimumab Treatment in Japanese Patients with Rheumatoid Arthritis from the Anouveau Study (Clinicaltrial.gov: NCT01346488)

    Yoshiya Tanaka1, Kiyotaka Yamazaki2, Ryo Nakajima2, Shuichi Komatsu3, Naoki Agata4, Ataru Igarashi5, Toshiro Tango6 and Tsutomu Takeuchi7, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2Post Marketing Study Group, Medical, AbbVie GK, Tokyo, Japan, 3Scientific Project Manager Group, Medical, AbbVie GK, Tokyo, Japan, 4Medical Communication, Medical, AbbVie GK, Tokyo, Japan, 5Department of Drug Policy & Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan, 6Center for Medical Statistics, Tokyo, Japan, 7Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Patients with Rheumatoid Arthritis (RA) experience loss of productivity such as missing their work and lowering their performance incurred by impaired physical functioning. Treatment…
  • Abstract Number: 3152 • 2016 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis (RA): Premature Use of Biologics Accelerating in United States (US)

    James R. O'Dell1, Stanley B. Cohen2, J Carter Thorne3 and Ted R Mikuls4, 1Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2Metroplex Clinical Research Center, Dallas, TX, 3Southlake Regional Health Centre, Newmarket, ON, Canada, 4Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: The treatment of RA has changed dramatically in the past several decades with the advent of a large number of new biologic agents as…
  • Abstract Number: 635 • 2016 ACR/ARHP Annual Meeting

    Factors Associated to Lack of Adherence to Subcutaneous Biological Medications in Patients with Rheumatoid Arthritis from Spain. Arco Study

    Jaime Calvo-Alen1, Indalecio Monteagudo2, Georgina Salvador Alarcón3, Enrique Raya Álvarez4, Loreto Carmona5, Luis Cea-Calvo6 and Carlos Marras Fernandez-Cid7, 1Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, 2Rheumatology Unit, HGU Gregorio Marañón, Madrid, Madrid, Spain, 3Rheumatology, HU Mutua de Terrassa, Barcelona, Terrassa, Spain, 4Rheumatology, Hospital Clínico San Cecilio, Granada, Spain, 5Instituto de Salud Musculoesquelética, Madrid, Spain, 6Medical Affairs Department, Merck Sharp & Dohme, Madrid, Spain, 7Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain

    Background/Purpose: To investigate the variables associated to lack of adherence to subcutaneous (SC) biological drug in patients with rheumatoid arthritis (RA) after 1 year of…
  • Abstract Number: 3222 • 2016 ACR/ARHP Annual Meeting

    Efficacy and Safety of Monotherapy with Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Compared with Adalimumab Monotherapy in Biologic-Naive Patients with Active Rheumatoid Arthritis: Results of a Global, Randomized, Double-Blind, Parallel-Group, Phase 3 Study

    Peter C. Taylor1, Michael Schiff2, Qingmin Wang3, Yusang Jiang3, Regina Kurrasch4, Shruti Daga5, Ravi Rao6, Benjamin Hsu3 and Paul-Peter Tak7, 1Kennedy Institute of Rheumatology, NDORMs, University of Oxford, Oxford, United Kingdom, 2University of Colorado, School of Medicine, Denver, CO, 3Janssen Research & Development, LLC, Spring House, PA, 4GlaxoSmithKline, Collegeville, PA, 5GlaxoSmithKline, Uxbridge, United Kingdom, 6GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, 7GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom

    Background/Purpose: Sirukumab, a human monoclonal antibody that selectively binds to the cytokine IL-6 with high affinity, is under development for rheumatoid arthritis (RA) and other…
  • Abstract Number: 649 • 2016 ACR/ARHP Annual Meeting

    Clinical Evaluation Usefulness of Standardized Protocol Strategies of Dose Reduction in Patients with Rheumatoid Arthritis in Clinical Remission Treated with Biologic Therapies. the Optibio Study

    Carmen Bejerano1, Natividad Oreiro1, Carlos Fernandez-Lopez2, Jose A Pinto-Tasende1, Antonio Atanes1, Bruno De Aspe1, Genaro Graña Gil1, Mercedes Freire1, Manuel Acasuso3, Sonia Pertega4, Francisco J. de Toro1 and Francisco J Blanco1, 1Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, 2Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruña, Spain, 3Centro de Salud San Jose, XAP Coruna, A Coruna, Spain, 4Epidemiology Unit, INIBIC - Complejo Hospitalario Universitario A Coruña, A Coruña, Spain

    Background/Purpose: The OPTIBIO study is a clinical trial whose primary endpoint is to evaluate the proportion of patients that after one year are maintained in…
  • Abstract Number: 3223 • 2016 ACR/ARHP Annual Meeting

    Efficacy and Safety of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study

    Daniel Aletaha1, Clifton Bingham III2, Yoshiya Tanaka3, Prasheen Agarwal4, Regina Kurrasch5, Paul-Peter Tak6 and Sharon Popik4, 1Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3University of Occupational and Environmental Health, Kitakyushu, Japan, 4Janssen Research & Development, LLC, Spring House, PA, 5GlaxoSmithKline, Collegeville, PA, 6GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom

    Background/Purpose: Sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity and is under development for rheumatoid arthritis (RA)…
  • Abstract Number: 1439 • 2016 ACR/ARHP Annual Meeting

    The EP4 Receptor Antagonist CR6086 Is More Effective Than Classical NSAID and DMARD Treatment in a Murine Model of Arthritis and in Human RA Synovial Explants

    Marije I. Koenders1, Monique M. Helsen1, Birgitte Walgreen1, Wim B. van den Berg1, Gianfranco Caselli2, Ornella Letari2 and Peter M. van der Kraan1, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 2Rottapharm Biotech, Monza, Italy

    Background/Purpose: CR6086 is a novel small molecule acting as a potent and selective antagonist of the prostaglandin E2 (PGE2) receptor EP4 subtype (EP4 receptor). Recent…
  • Abstract Number: 3224 • 2016 ACR/ARHP Annual Meeting

    Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Based upon Prior Use of Non-Anti-TNF Biologics in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global Phase 3 Study

    Yoshiya Tanaka1, Daniel Aletaha2, Clifton Bingham III3, Prasheen Agarwal4, Regina Kurrasch5 and Sharon Popik4, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Janssen Research & Development, LLC, Spring House, PA, 5GlaxoSmithKline, King of Prussia, PA

    Background/Purpose: A global, phase 3 study (SIRROUND-T) evaluating the efficacy and safety of sirukumab, a selective, high-affinity human monoclonal antibody to IL-6, has recently been…
  • Abstract Number: 1615 • 2016 ACR/ARHP Annual Meeting

    Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Significantly Improves Physical Function and Reduces Morning Stiffness in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global, Randomized, Placebo-Controlled, Phase 3 Trial

    Yoshiya Tanaka1, Clifton Bingham III2, Daniel Aletaha3, Prasheen Agarwal4, Sharon Popik4, Regina Kurrasch5, Steve Peterson4, Rita Ganguly5, Chenglong Han4 and Kelly McQuarrie4, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 4Janssen Research & Development, LLC, Spring House, PA, 5GlaxoSmithKline, Collegeville, PA

    Background/Purpose: Improvement in physical function and morning stiffness are key goals of rheumatoid arthritis (RA) treatment.  Sirukumab, a selective human anti–IL6 monoclonal antibody, has recently…
  • Abstract Number: 1625 • 2016 ACR/ARHP Annual Meeting

    Analysis of a Phase 3 Study Evaluating the Efficacy of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Across Subgroups in Patients with Active Rheumatoid Arthritis Despite Treatment with Disease-Modifying Anti-Rheumatic Drugs

    Carter Thorne1, George Karpouzas2, Tsutomu Takeuchi3, Shihong Sheng4, Weichun Xu4, Ravi Rao5, Kaiyin Fei4 and Benjamin Hsu4, 1University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, 2Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, 3Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, 4Janssen Research & Development, LLC, Spring House, PA, 5GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom

    Background/Purpose: Sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, and is under development for rheumatoid arthritis (RA)…
  • Abstract Number: 1641 • 2016 ACR/ARHP Annual Meeting

    Survival of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

    Zulema Rosales Rosado1,2, Leticia León1, Dalifer Freites Núñez2, Judit Font Urgelles2, Cynthia Milagros León Cárdenas2, Cristina Vadillo Font2, Luis Rodriguez Rodriguez1, Juan A Jover Jover2 and Lydia Abásolo Alcázar1, 1Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, 2Rheumatology, Hospital Clínico San Carlos, Madrid, Spain

    Background/Purpose:  After more than twenty years using Disease Modifying Drugs (DMARDs) is widely known their efficacy in the treatment of Rheumatoid Arthritis (RA) but it…
  • Abstract Number: 2233 • 2016 ACR/ARHP Annual Meeting

    Predictors of Adherence and Costs in First and Second Years after Biologic Initiation in Patients with Rheumatoid Arthritis (RA)

    Bradley S. Stolshek1, Sally W. Wade2, Ajita De3, Ron L. Wade3 and Jason Yeaw3, 1Amgen, Thousand Oaks, CA, 2Wade Outcomes Research and Consulting, Salt Lake City, UT, 3IMS Health, Plymouth Meeting, PA

    Background/Purpose:   Rheumatoid arthritis (RA) is a chronic disease requiring continuous therapy to reach low disease activity targets and to delay its long-term health effects.…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology